SCHEMBL4585127

SCHEMBL4585127

CC(Cl)(CCc1ccccc1)P(=O)(O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 10/20 0.51
GGPS1 O95749 1/20 0.46
TSHR P16473 1/20 0.44
ANPEP P15144 3/20 0.42
ERAP1 Q9NZ08 2/20 0.42
ERAP2 Q6P179 2/20 0.42
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CETP P11597 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP3 P08254 1/20 0.41
CA9 Q16790 1/20 0.41
ACP3 P15309 1/20 0.41
S1PR2 O95136 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28408596 0.74 ALDH1A1 (0.44)
SCHEMBL12266021 0.74 ALDH1A1 (0.47) MEN1HTTKMT2AL3MBTL1
SCHEMBL29223826 0.74 ALDH1A1 (0.47) MEN1HTTKMT2AL3MBTL1
SCHEMBL11666362 0.74 HDAC3 (0.49) FDPSGGPS1TSHRANPEPERAP1
SCHEMBL11780297 0.73 KEAP1 (0.48) MEN1KMT2A
SCHEMBL3361664 0.71 FDPS (0.59) FDPSGGPS1TSHRANPEPERAP1
SCHEMBL9119940 0.71 ALDH1A1 (0.43) MEN1KMT2A
Phosphoric Acid SCHEMBL412030 0.71 TSHR (0.61) FDPSTSHRANPEPERAP1ERAP2
SCHEMBL11293428 0.70 MEN1 (0.47) FDPSMEN1HTTKMT2AL3MBTL1
SCHEMBL11498672 0.70 ALDH1A1 (0.52) FDPSTSHRMEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1385988-A4 SELECTIVE COVALENT-BINDING COMPOUNDS HAVING THERAPEUTIC DIAGNOSTIC AND ANALYTICAL APPLICATIONS SEMOREX INC (US) 2008-04-09 EP disclosed
US-20040121405-A1 Selective covalent-binding compounds having therapeutic diagnostic and analytical applications SEMOREX INC. 2004-06-24 US disclosed
EP-1385988-A2 SELECTIVE COVALENT-BINDING COMPOUNDS HAVING THERAPEUTIC DIAGNOSTIC AND ANALYTICAL APPLICATIONS Semorex Inc. (US) 2004-02-04 EP disclosed
WO-2002083708-A2 SELECTIVE COVALENT-BINDING COMPOUNDS HAVING THERAPEUTIC DIAGNOSTIC AND ANALYTICAL APPLICATIONS SEMOREX INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121405-A1 Selective covalent-binding compounds having therapeutic diagnostic and analytical applications CD2BP2, HAVCR2, EPCAM FDPS 4263/4885GGPS1 4839/4885TSHR 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.